Identification of epigenetically silenced genes in tumor endothelial cells

Cancer Research

Volumn 67, Issue 9, 2007, Pages 4138-4148

  Hellebrekers, Debby M E I ^a   Melotte, Veerle ^a   Viré, Emmanuelle ^b   Langenkamp, Elise ^c   Molema, Grietje ^c   Fuks, François ^b   Herman, James G ^d   Van Criekinge, Wim ^e   Griffioen, Arjan W ^a   Van Engeland, Manon ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b FREE UNIVERSITY OF BRUSSELS   (Belgium)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CLUSTERIN; ENDOTHELIAL CELL GROWTH FACTOR; FIBRILLIN 1; HISTONE H3; LYSINE; MESSENGER RNA; RNA; TRICHOSTATIN A;

ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; CPG ISLAND; DEACETYLATION; DNA METHYLATION; DNA MODIFICATION; DOWN REGULATION; ENDOTHELIUM CELL; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE SILENCING; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; MICRODISSECTION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; RNA INTERFERENCE; SPROUTING; TUMOR CELL; TUMOR GENE; UNINDEXED SEQUENCE;

AZACITIDINE; CACO-2 CELLS; CLUSTERIN; COLONIC NEOPLASMS; DNA METHYLATION; DNA MODIFICATION METHYLASES; ENDOTHELIAL CELLS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MICROFILAMENT PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THIOREDOXIN;

EID: 34249323034     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3032     Document Type: Article

References (50)

1. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005;438:932-6.
2. St Croix B, Rago C, Velculescu V, et al. Genes expressed in human tumor endothelium. Science 2000; 289:1197-202.
3. Bicknell R, Harris AL. Novel angiogenic signaling pathways and vascular targets. Annu Rev Pharmacol Toxicol 2004;44:219-38.
4. van Beijnum J, Dings RP, van der Linden E, et al. Gene expression of tumor angiogenesis dissected; specific targeting of colon cancer angiogenic vasculature. Blood 2006;108:2339-48.
5. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000;403:41-5.
6. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003;33 Suppl:245-54.
7. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54.
8. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999;21:103-7.
9. Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006;5:37-50.
10. Suzuki H, Gabrielson E, Chen W, et al. A genomic screen for genes up-regulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 2002;31:141-9.
11. Yamashita K, Upadhyay S, Osada M, et al. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2002;2:485-95.
12. Hellebrekers DM, Jair KW, Vire E, et al. Angiostatic activity of DNA methyltransferase inhibitors. Mol Cancer Ther 2006;5:467-75.
13. Kim MS, Kwon HJ, Lee YM, et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001;7:437-43.
14. Deroanne CF, Bonjean K, Servotte S, et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 2002;21:427-36.
15. van der Schaft DW, Toebes EA. Haseman JR. Mayo KM, Griffioen AW. Bactericidal/permeability-increasing protein (BPI) inhibits angiogenesis via induction of apoptosis in vascular endothelial cells. Blood 2000;96: 176-81.
16. Thijssen VL, Brandwijk RJ, Dings RP, Griffioen AW. Angiogenesis gene expression profiling in xenograft models to study cellular interactions. Exp Cell Res 2004; 299:286-93.
17. Metivier R, Penot G, Hubner MR, et al. Estrogen receptor-α directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 2003;115:751-63.
18. van der Schaft DW, Dings RP, de Lussanet QG, et al. The designer anti-angiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models. FASEB J 2002;16:1991-3.
19. Gardiner-Garden M, Frommer M. CpG islands in vertebrate genomes. J Mol Biol 1987;196:261-82.
20. Cross SH, Charlton JA, Nan X, Bird AP. Purification of CpG islands using a methylated DNA binding column. Nat Genet 1994;6:236-44.
21. Lund P, Weisshaupt K, Mikeska T, et al. Oncogenic HRAS suppresses clusterin expression through promoter hypermethylation. Oncogene 2006;25:4890-903.
22. Chan GC, Fish JE, Mawji IA, Leung DD, Rachlis AC, Marsden PA. Epigenetic basis for the transcriptional hyporesponsiveness of the human inducible nitric oxide synthase gene in vascular endothelial cells. J Immunol 2005;175:3846-61.
23. Franklin SL, Ferry RJ, Jr., Cohen P. Rapid insulin-like growth factor (IGF)-independent effects of IGF binding protein-3 on endothelial cell survival. J Clin Endocrinol Metab 2003;88:900-7.
24. Iwatsuki K, Tanaka K, Kaneko T, et al. Runx1 promotes angiogenesis by down regulation of insulin-like growth factor-binding protein-3. Oncogene 2004;24:1129-37.
25. Griffioen AW, Damen CA, Martinotti S, Blijham GH, Groenewegen G. Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. Cancer Res 1996; 56:1111-7.
26. Jackson JK, Gleave ME, Gleave J, Burt HM. The inhibition of angiogenesis by antisense oligonucleotides to clusterin. Angiogenesis 2005;8:229-38.
27. Sivamurthy N. Stone DH, LoGerfo FW, Quist WC. Apolipoprotein J inhibits the migration and adhesion of endothelial cells. Surgery 2001;130:204-9.
28. Bender CM, Pao MM, Jones PA. Inhibition of DNA methylation by 5-aza-2′-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res 1998;58: 95-101.
29. Marks PA, Richon VM, Kelly WK, Chiao JH, Miller T. Histone deacetylase inhibitors: development as cancer therapy. Novartis Found Symp 2004;259:269-81; discussion 81-8.
30. Qian DZ, Wang X, Kachhap SK, et al. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 2004;64: 6626-34.
31. Rossig L, Li H, Fisslthaler B, et al. Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis. Circ Res 2002;91:837-44.
32. Friedrich MG, Chandrasoma S, Siegmund KD, et al. Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. Eur J Cancer 2005;41:2769-78.
33. Chang YS, Wang L, Liu D, et al. Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clin Cancer Res 2002;8:3669-75.
34. Miyamoto K, Fukutomi T, Akashi-Tanaka S, et al. Identification of 20 genes aberrantly methylated in human breast cancers. Int J Cancer 2005;116:407-14.
35. Chiba T, Yokosuka O, Fukai K, et al. Cell growth inhibition and gene expression induced by the histone deacetylase inhibitor, trichostatin A, on human hepatoma cells. Oncology 2004;66:481-91.
36. Tamaru II, Selker EU. A histone H3 methyltransferase controls DNA methylation in Neurospora crassa. Nature 2001;414:277-83.
37. Bachman KE, Park BH, Rhee I, et al. Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell 2003;3:89-95.
38. Nguyen CT, Weisenberger DJ, Velicescu M, et al. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2′-deoxycytidine. Cancer Res 2002;62: 6456-61.
39. Schmelz K, Sattler N, Wagner M, Lubbert M, Dorken B, Tamm I. Induction of gene expression by 5-Aza-2′-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms. Leukemia 2005;19:103-11.
40. Fuks F, Burgers WA, Brehm A, Hughes-Davies L, Kouzarides T. DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat Genet 2000;24:88-91.
41. Lehnertz B, Ueda Y, Derijck AA, et al. Suv39h-mediated histone H3 lysine 9 methylation directs DNA methylation to major satellite repeats at pericentric heterochromatin. Curr Biol 2003;13:1192-200.
42. Robertson KD, Ait-Si-Ali S, Yokochi T, Wade PA, Jones PL, Wolffe AP. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat Genet 2000;25:338-42.
43. Rountree MR, Bachman KE, Baylin SB. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat Genet 2000;25:269-77.
44. Coppock DL, Cina-Poppe D, Gilleran S. The quiescin Q6 gene (QSCN6) is a fusion of two ancient gene families: thioredoxin and ERV1. Genomics 1998;54:460-8.
45. Chen T, Turner J, McCarthy S, Scaltriti M, Bettuzzi S, Yeatman TJ. Clusterin-mediated apoptosis is regulated by adenomatous polyposis coli and is p21 dependent but p53 independent. Cancer Res 2004;64:7412-9.
46. Zhang H, Kim JK, Edwards CA, Xu Z, Taichman R, Wang CY. Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol 2005;7:909-15.
47. Leskov KS, Klokov DY, Li J, Kinsella TJ, Boothman DA. Synthesis and functional analyses of nuclear clusterin, a cell death protein. J Biol Chem 2003;278: 11590-600.
48. Handford PA. Fibrillin-1, a calcium binding protein of extracellular matrix. Biochim Biophys Acta 2000;1498: 84-90.
49. Carta L, Pereira L, Arteaga-Solis E, et al. Fibrillins 1 and 2 perform partially overlapping functions during aortic development. J Biol Chem 2006;281:8016-23.
50. Wilson DG, Bellamy MF, Ramsey MW, et al. Endothelial function in Marfan syndrome: selective impairment of flow-mediated vasodilation. Circulation 1999;99:909-15.